SEARCH

SEARCH BY CITATION

References

  • 1
    Sartor RB. Microbial influences in inflammatory bowel disease; role in pathogenesis and clinical implications. In: Sartor, RB, Sandbom, WJ eds. Klisner's Inflammatory Bowel Disease, 6th edn. Edinburgh: Elsevier, 2003: 13862.
  • 2
    Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 162033.
  • 3
    Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120: 62235.
  • 4
    Onderdonk AB, Bronson R, Cisneros R. Comparison of Bacteroides vulgatus strains in the enhancement of experimental ulcerative colitis. Infect Immun 1987; 55: 8356.
  • 5
    Ohkusa T, Okayasu I, Ogihara T, et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 7983.
  • 6
    Poxton IR, Brown R, Sawyerr A, et al. Mucosa-associated bacterial flora of the human colon. J Med Microbiol 1997; 46: 8591.
  • 7
    Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut 1994; 35: 65864.
  • 8
    Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989; 66: 36578.
  • 9
    Shanahan F. Probiotics in inflammatory bowel disease–therapeutic rationale and role. Adv Drug Deliv Rev 2004; 56: 80918.
  • 10
    Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998; 42: 27.
  • 11
    Fabia R, Ar'Rajab A, Johansson ML, et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol 1993; 28: 15562.
  • 12
    Mao Y, Nobaek S, Kasravi B, et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 1996; 111: 33444.
  • 13
    Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 110714.
  • 14
    Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazinein maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 8538.
  • 15
    Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 6359.
  • 16
    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 3059.
  • 17
    Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL #3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 10814.
  • 18
    Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 12029.
  • 19
    Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk onulcerative colitis. J Am Coll Nutr 2003; 22: 5663.
  • 20
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 1955; 2: 1041.
  • 21
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 18415.
  • 22
    Harig JM, Soergel KH, Komorowski RA, et al. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989; 320: 238.
  • 23
    Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992; 103: 516.
  • 24
    Matts SGF. Quart J Med 1961; 120: 393407.
  • 25
    Mitsuyama K, Saiki T, Kanauchi O, et al. Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment Pharmacol Ther 1998; 12: 122530.
  • 26
    Requena TJ, Burton IT, Matsuki K et al. Tannock identification, detection, and enumeration of human bifidobacterium species by PCR targeting the transaldolase gene. Appl Environ Microbiol 2002; 68: 24207.
  • 27
    Matuski T, Watanabe K, Fujimoto J, et al. Quantitative PCR with 16S-rRNA-gene targeted species-specific primers for analysis of human intestinal bifidobacteria. Appl Environ Microbiol 2004; 70: 16773.
  • 28
    Miyamoto Y, Watanabe K, Tanaka R, et al. Distribution analysis of six predominant Bacteroides species in normal human feces using 16S rDNA-targeted species-specific primers. Microbial Ecol Health Dis 2002; 14: 1336.
  • 29
    Sakata T, Kojima T, Fujieda M, et al. Influences of probiotic bacteria on organic acid production by pig caecal bacteria in vitro. Proc Nutr Soc 2003; 62: 7380.
  • 30
    Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 2001; 276: 446416.
  • 31
    Chapman MA, Grahn MF, Boyle MA, et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut 1994; 35: 736.
  • 32
    Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci 1996; 41: 22549.
  • 33
    Kitajima H, Sumida Y, Tanaka R, et al. Early administration of Bifidobacterium breve to preterm infants: randomized controlled trial. Arch Dis Child 1997; 76: F1017.
  • 34
    Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344: 10469.
  • 35
    Matsuda H, Fujiyama Y, Andoh A, et al. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol 2000; 15: 618.
  • 36
    Setoyama H, Imaoka A, Ishikawa H, et al. Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect 2003; 5: 11522.